Back to top
more

Teleflex (TFX)

(Delayed Data from NYSE)

$201.92 USD

201.92
640,750

-1.58 (-0.78%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.74 -0.18 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

by Zacks Equity Research

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Compared to Estimates, Teleflex (TFX) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 3.68% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 10.13% and 6.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Countdown to Teleflex (TFX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Teleflex (TFX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 12.90% and 0.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.98% and 2.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for OUSM

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

Why Is Waters (WAT) Up 13.2% Since Last Earnings Report?

by Zacks Equity Research

Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC

by Zacks Equity Research

Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.

Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry

by Zacks Equity Research

Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Teleflex (TFX) Q3 Earnings Top Estimates, 2023 Outlook Up

by Zacks Equity Research

Teleflex's (TFX) year-over-year revenue growth was driven by all global product categories in Q3.

Compared to Estimates, Teleflex (TFX) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) to Report Q3 Results: What to Know Ahead of the Release

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Advances Urology Portfolio With New Buyout

by Zacks Equity Research

Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.

Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures

by Zacks Equity Research

With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.